 Connection
Paul Bunn to Dose-Response Relationship, Drug
This is a "connection" page, showing publications Paul Bunn has written about Dose-Response Relationship, Drug.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.489 |
|
|
|
-
Helfrich BA, Kim J, Gao D, Chan DC, Zhang Z, Tan AC, Bunn PA. Barasertib (AZD1152), a Small Molecule Aurora B Inhibitor, Inhibits the Growth of SCLC Cell Lines In Vitro and In Vivo. Mol Cancer Ther. 2016 10; 15(10):2314-2322.
Score: 0.100
-
Bunn PA. Diseases desperate grown. J Natl Cancer Inst. 2008 Apr 16; 100(8):520-1.
Score: 0.056
-
Helfrich BA, Raben D, Varella-Garcia M, Gustafson D, Chan DC, Bemis L, Coldren C, Bar?n A, Zeng C, Franklin WA, Hirsch FR, Gazdar A, Minna J, Bunn PA. Antitumor activity of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor gefitinib (ZD1839, Iressa) in non-small cell lung cancer cell lines correlates with gene copy number and EGFR mutations but not EGFR protein levels. Clin Cancer Res. 2006 Dec 01; 12(23):7117-25.
Score: 0.051
-
Kelly K, Mikhaeel-Kamel N, Pan Z, Murphy J, Prindiville S, Bunn PA. A phase I/II trial of paclitaxel, carboplatin, and gemcitabine in untreated patients with advanced non-small cell lung cancer. Clin Cancer Res. 2000 Sep; 6(9):3474-9.
Score: 0.033
-
Bunn PA, Kelly K. New combinations in the treatment of lung cancer: a time for optimism. Chest. 2000 Apr; 117(4 Suppl 1):138S-143S.
Score: 0.032
-
Kelly K, Pan Z, Wood ME, Murphy J, Bunn PA. A phase I study of paclitaxel, etoposide, and cisplatin in extensive stage small cell lung cancer. Clin Cancer Res. 1999 Nov; 5(11):3419-24.
Score: 0.031
-
Bunn PA, Helfrich BA, Brenner DG, Chan DC, Dykes DJ, Cohen AJ, Miller YE. Effects of recombinant neutral endopeptidase (EC 3.4.24.11) on the growth of lung cancer cell lines in vitro and in vivo. Clin Cancer Res. 1998 Nov; 4(11):2849-58.
Score: 0.029
-
Kelly K, Pan Z, Murphy J, Huffman DH, Bunn PA. A phase I trial of paclitaxel plus carboplatin in untreated patients with advanced non-small cell lung cancer. Clin Cancer Res. 1997 Jul; 3(7):1117-23.
Score: 0.027
-
Bunn PA, Kelly K. A phase I study of carboplatin and paclitaxel in non-small cell lung cancer: a University of Colorado Cancer Center study. Semin Oncol. 1995 Aug; 22(4 Suppl 9):2-6.
Score: 0.023
-
Bunn PA, Chan D, Dienhart DG, Tolley R, Tagawa M, Jewett PB. Neuropeptide signal transduction in lung cancer: clinical implications of bradykinin sensitivity and overall heterogeneity. Cancer Res. 1992 Jan 01; 52(1):24-31.
Score: 0.018
-
Weiss GJ, Vokes EE, Bunn PA, Magree L, Rusk J, Albert D, Kelly K. Docetaxel and exisulind in previously treated non-small cell lung cancer (NSCLC) patients: a multicenter, phase II clinical trial. J Thorac Oncol. 2007 Oct; 2(10):933-8.
Score: 0.014
-
Bunn PA, Ihde DC, Foon KA. Recombinant interferon alfa-2a, an active agent in advanced cutaneous T-cell lymphomas. Int J Cancer Suppl. 1987; 1:9-13.
Score: 0.013
-
Thienelt CD, Bunn PA, Hanna N, Rosenberg A, Needle MN, Long ME, Gustafson DL, Kelly K. Multicenter phase I/II study of cetuximab with paclitaxel and carboplatin in untreated patients with stage IV non-small-cell lung cancer. J Clin Oncol. 2005 Dec 01; 23(34):8786-93.
Score: 0.012
-
Witta SE, Gustafson DL, Pierson AS, Menter A, Holden SN, Basche M, Persky M, O'Bryant CL, Zeng C, Baron A, Long ME, Gibbs A, Kelly K, Bunn PA, Chan DC, Pallansch P, Eckhardt SG. A phase I and pharmacokinetic study of exisulind and docetaxel in patients with advanced solid tumors. Clin Cancer Res. 2004 Nov 01; 10(21):7229-37.
Score: 0.011
-
Khorana A, Bunn P, McLaughlin P, Vose J, Stewart C, Czuczman MS. A phase II multicenter study of CAMPATH-1H antibody in previously treated patients with nonbulky non-Hodgkin's lymphoma. Leuk Lymphoma. 2001 Mar; 41(1-2):77-87.
Score: 0.009
-
Bunn PA, Shackney SE, Ford SS. The effects of colcemid on hematopoiesis in the mouse. J Clin Invest. 1976 Nov; 58(5):1280-5.
Score: 0.006
-
Kelly K, Crowley JJ, Bunn PA, Hazuka MB, Beasley K, Upchurch C, Weiss GR, Hicks WJ, Gandara DR, Rivkin S, et al. Role of recombinant interferon alfa-2a maintenance in patients with limited-stage small-cell lung cancer responding to concurrent chemoradiation: a Southwest Oncology Group study. J Clin Oncol. 1995 Dec; 13(12):2924-30.
Score: 0.006
-
Bunn PA, Okamoto M, Riker WF. Further observations on subacute denervation and mammalian motor nerve terminal function. Neurology. 1973 Jan; 23(1):12-20.
Score: 0.005
-
Kohn EC, Steis RG, Sausville EA, Veach SR, Stocker JL, Phelps R, Franco S, Longo DL, Bunn PA, Ihde DC. Phase II trial of intermittent high-dose recombinant interferon alfa-2a in mycosis fungoides and the S?zary syndrome. J Clin Oncol. 1990 Jan; 8(1):155-60.
Score: 0.004
-
Keenan AM, Weinstein JN, Carrasquillo JA, Bunn PA, Reynolds JC, Foon KA, Smarte NC, Ghosh B, Fejka RM, Larson SM, et al. Immunolymphoscintigraphy and the dose dependence of 111In-labeled T101 monoclonal antibody in patients with cutaneous T-cell lymphoma. Cancer Res. 1987 Nov 15; 47(22):6093-9.
Score: 0.003
-
Ihde DC, Deisseroth AB, Lichter AS, Bunn PA, Carney DN, Cohen MH, Veach SR, Makuch RW, Johnston-Early A, Abrams RA, et al. Late intensive combined modality therapy followed by autologous bone marrow infusion in extensive-stage small-cell lung cancer. J Clin Oncol. 1986 Oct; 4(10):1443-54.
Score: 0.003
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|